No FDA-approved stem-cell therapy exists for cerebral palsy. Several products are in Phase 1–2; none has completed Phase 3. Physiotherapy, botulinum toxin and surgery are established; stem cells are investigational. 'FDA approval' claims for cerebral-palsy stem-cell treatments should be disregarded.
Cerebral palsy results from non-progressive brain injury around the time of birth, producing motor dysfunction, spasticity and variable cognitive or sensory impairment. Stem-cell research targets neuroprotection and plasticity: placental mesenchymal stem cells are studied for anti-inflammatory effects that may limit secondary neuronal loss and reduce spasticity, while neurogenic cells are explored to support damaged motor circuitry and synaptic reorganisation. Because the brain injury is fixed, intervention aims to limit secondary damage and enhance plasticity rather than reverse established damage. Trials enrol children and young adults; reported outcomes include spasticity reduction and motor-function changes, usually alongside intensive physiotherapy.
Am I a candidate? → · Cerebral Palsy: full overview → · Cerebral Palsy cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita